Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.

Circulation - 29 Aug 2000

Priori S G, Napolitano C, Schwartz P J, Bloise R, Crotti L, Ronchetti E

Abstract excerpt

BACKGROUND: Defects of the SCN5A gene encoding the cardiac sodium channel are associated with both the LQT3 subtype of long-QT syndrome and Brugada syndrome (BS). The typical manifestations of long-QT syndrome (QT interval prolongation) and BS (ST segment elevation in leads V1 through V3) may coexist in the same patients, which raises questions about the actual differences between LQT3 and BS. Intravenous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anti-Arrhythmia Agents
Share to Contraindications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flecainide

Share to Injections, Intravenous

Share to Long QT Syndrome

Share to Sodium Channel Blockers

Share to Sodium Channels

Source

Identifiers

PMID: 10961955
DOI: 10.1161/01.cir.102.9.945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.PMID 10961955Read ↗

Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome.Semantic proximity Read ↗

Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease.Semantic proximity Read ↗

Long-term flecainide therapy in type 3 long QT syndrome.Semantic proximity Read ↗

A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.Semantic proximity Read ↗

Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.Semantic proximity Read ↗

Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.Semantic proximity Read ↗

Flecainide test in Brugada syndrome: a reproducible but risky tool.Semantic proximity Read ↗

The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.Semantic proximity Read ↗

Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?Semantic proximity Read ↗

Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.Semantic proximity Read ↗

Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.Semantic proximity Read ↗

Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.